SCHEMBL16183255

SCHEMBL16183255

Fc1cc(-c2ccccc2)cc2c(NCc3ccccn3)nc(-c3ccccc3)nc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 3/20 0.65
KCNA5 P22460 6/20 0.49
KCNH2 Q12809 4/20 0.49
HIF1A Q16665 1/20 0.49
GBA1 P04062 3/20 0.47
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
JAK2 O60674 1/20 0.46
LCK P06239 1/20 0.46
LYN P07948 1/20 0.46
CDK2 P24941 1/20 0.46
TYK2 P29597 1/20 0.46
TXK P42681 1/20 0.46
NR2C2 P49116 1/20 0.46
GSK3B P49841 1/20 0.46
IRAK1 P51617 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16183240 0.92 KCNA5 (0.57) PDE5AKCNA5KCNH2GBA1ALDH1A1
SCHEMBL14474584 0.80 MAPT (0.55) PDE5AKCNA5KCNH2HIF1AGBA1
SCHEMBL14727721 0.80 KCNA5 (0.54) PDE5AKCNA5KCNH2GBA1ALDH1A1
SCHEMBL1062608 0.79 PDE5A (1.00) PDE5AKCNA5KCNH2GBA1MAPT
SCHEMBL17212407 0.77 PDE5A (0.68) PDE5AKCNA5KCNH2GBA1MAPT
SCHEMBL16185171 0.76 ALDH1A1 (0.67) PDE5AHIF1AGBA1MAPTKDM4E
SCHEMBL16183709 0.76 PDE5A (0.60) PDE5AKCNA5KCNH2GBA1ALDH1A1
SCHEMBL16183708 0.76 PDE5A (0.68) PDE5AKCNA5KCNH2GBA1ALDH1A1
SCHEMBL16183711 0.74 KCNA5 (0.66) PDE5AKCNA5KCNH2HIF1AGBA1
SCHEMBL16183710 0.74 PDE5A (0.63) PDE5AKCNA5KCNH2GBA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB PDE5A 704/4885KCNA5 4457/4885KCNH2 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.